Bausch Health Companies Inc. (BHC) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Bausch Health Companies Inc. Do?
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada. Bausch Health Companies Inc. (BHC) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Thomas J. Appio and employs approximately 19,900 people, headquartered in Laval, Quebec. With a market capitalization of $2.1B, BHC is one of the notable companies in the Healthcare sector.
Bausch Health Companies Inc. (BHC) Stock Rating — Reduce (April 2026)
As of April 2026, Bausch Health Companies Inc. receives a Reduce rating with a composite score of 43.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BHC ranks #2,921 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Bausch Health Companies Inc. ranks #413 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
BHC Stock Price and 52-Week Range
Bausch Health Companies Inc. (BHC) currently trades at $5.60. The stock gained $0.21 (3.9%) in the most recent trading session. The 52-week high for BHC is $8.69, which means the stock is currently trading -35.5% from its annual peak. The 52-week low is $4.25, putting the stock 31.8% above its annual trough. Recent trading volume was 1.7M shares, reflecting moderate market activity.
Is BHC Overvalued or Undervalued? — Valuation Analysis
Bausch Health Companies Inc. (BHC) carries a value factor score of 70/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 14.88x, compared to the Healthcare sector average of 23.63x — a discount of 37%. The price-to-book ratio stands at 5.17x, versus the sector average of 2.75x. The price-to-sales ratio is 0.20x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, BHC trades at 7.86x EV/EBITDA, versus 6.34x for the sector.
Based on these multiples, Bausch Health Companies Inc. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.
Bausch Health Companies Inc. Profitability — ROE, Margins, and Quality Score
Bausch Health Companies Inc. (BHC) earns a quality factor score of 45/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 34.8%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 0.5% versus the sector average of -33.1%.
On a margin basis, Bausch Health Companies Inc. reports gross margins of 72.0%, compared to 71.5% for the sector. The operating margin is 16.4% (sector: -66.1%). Net profit margin stands at 1.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 11.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
BHC Debt, Balance Sheet, and Financial Health
Bausch Health Companies Inc. has a debt-to-equity ratio of 5522.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.47x, suggesting adequate working capital coverage. Total debt on the balance sheet is $20.82B. Cash and equivalents stand at $1.31B.
BHC has a beta of 1.08, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Bausch Health Companies Inc. is 45/100, reflecting average volatility within the normal range for its sector.
Bausch Health Companies Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Bausch Health Companies Inc. reported revenue of $9.98B and earnings per share (EPS) of $0.42. Net income for the quarter was $131M. Gross margin was 72.0%. Operating income came in at $1.66B.
In FY 2025, Bausch Health Companies Inc. reported revenue of $10.27B and earnings per share (EPS) of $0.42. Net income for the quarter was $120M. Revenue grew 6.7% year-over-year compared to FY 2024. Operating income came in at $1.81B.
In Q3 2025, Bausch Health Companies Inc. reported revenue of $2.68B and earnings per share (EPS) of $0.48. Net income for the quarter was $181M. Revenue grew 6.8% year-over-year compared to Q3 2024. Operating income came in at $619M.
In Q2 2025, Bausch Health Companies Inc. reported revenue of $2.53B and earnings per share (EPS) of $0.40. Net income for the quarter was $128M. Revenue grew 5.3% year-over-year compared to Q2 2024. Operating income came in at $444M.
Over the past 8 quarters, Bausch Health Companies Inc. has demonstrated a growth trajectory, with revenue expanding from $2.40B to $9.98B. Investors analyzing BHC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
BHC Dividend Yield and Income Analysis
Bausch Health Companies Inc. (BHC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
BHC Momentum and Technical Analysis Profile
Bausch Health Companies Inc. (BHC) has a momentum factor score of 27/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.
BHC vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Bausch Health Companies Inc. (BHC) ranks #413 out of 838 stocks based on the Blank Capital composite score. This places BHC in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing BHC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BHC vs S&P 500 (SPY) comparison to assess how Bausch Health Companies Inc. stacks up against the broader market across all factor dimensions.
BHC Next Earnings Date
No upcoming earnings date has been announced for Bausch Health Companies Inc. (BHC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy BHC? — Investment Thesis Summary
The quantitative profile for Bausch Health Companies Inc. suggests caution. The value score of 70/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 27/100, a headwind for near-term performance.
In summary, Bausch Health Companies Inc. (BHC) earns a Reduce rating with a composite score of 43.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BHC stock.
Related Resources for BHC Investors
Explore more research and tools: BHC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BHC head-to-head with peers: BHC vs AZN, BHC vs SLGL, BHC vs VMD.